


Photoredox-catalyzed reaction as a powerful tool for rapid natural product *Gem*-dimethylation modification: discovery of potent anti-cancer agents with improved druggability

Graphical abstract



Highlights

- A novel photoredox methodology was used to modify tylophorine, resulting in the synthesis of a *gem*-dimethyl tylophorine analogue, which was designated **compound 4b**.
- **Compound 4b** demonstrated promising activity against a wide range of tumor cell lines and exhibited significantly improved drug-like properties.
- **Compound 4b** showed exceptional inhibitory effect against a C481S mutation-induced ibrutinib-resistant non-Hodgkin's lymphoma cell line, as well as primary tumor cell lines obtained from patients.

Authors

Chao Zhang, Yugang Song, Xiuyun Sun, Qianlong Liu, Zhen Li, Shenyi Yin, Jianzhong Jeff Xi, Xin Zhai and Yu Rao

Correspondence

yrao@tsinghua.edu.cn (Y. Rao)
zhaixin_syphu@126.com (X. Zhai)

In brief

Gem-dimethyl tylophorine analogue, designated as **compound 4b**, demonstrated potent anti-cancer activity against various tumor cell lines, along with highly improved drug-like properties.

Short Communication

Photoredox-catalyzed reaction as a powerful tool for rapid natural product *Gem*-dimethylation modification: discovery of potent anti-cancer agents with improved druggability

Chao Zhang^{a,1}, Yugang Song^{a,1}, Xiuyun Sun^a, Qianlong Liu^a, Zhen Li^b, Shenyi Yin^c, Jianzhong Jeff Xi^c, Xin Zhai^{b,*} and Yu Rao^{a,*}

^aMOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing 100084, China

^bKey Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China

^cState Key Laboratory of Natural and Biomimetic Drugs, Institute of Molecular Medicine, Department of Biomedical Engineering, College of Engineering, Peking University, Beijing 100871, China

¹C.Z. and Y.G.S. contributed equally.

*Correspondence: yrao@tsinghua.edu.cn (Y. Rao); zhaixin_syphu@126.com (X. Zhai)

Received: 14 August 2023; Revised: 5 October 2023; Accepted: 11 October 2023

Published online: 28 October 2023

DOI 10.15212/AMM-2023-0032

ABSTRACT

Tylophorine has diverse biological activities; however, the stability, solubility, and central nervous system toxicity have severely limited use of tylophorine. The *gem*-dimethyl group is an organic chemistry functional group that consists of two methyl groups bonded to the same carbon atom. This feature has gained significant attention in medicinal chemistry due to its unique properties and potential applications in drug design. We applied a new photoredox methodology to tylophorine modification, resulting in a series of *gem*-dimethyl tylophorine analogues. Among the analogues, **compound 4b** demonstrated promising activity against a wide range of tumor cell lines and exhibited significantly improved drug-like properties, including enhanced solubility and stability. **Compound 4b** showed an exceptional inhibitory effect (7.8 nM) against a C481S mutation-induced ibrutinib-resistant non-Hodgkin's lymphoma cell line, as well as primary tumor cell lines obtained from patients. Importantly, **compound 4b** exhibited significantly reduced anti-proliferative activity against the normal cell line tested, indicating the potential for an enhanced therapeutic window for **compound 4b**. Based on these early-stage data, we believe that our study provides a solid foundation for the development of new therapeutic agents for potential drug-resistant cancer treatment in the near future.

Keywords: Photoredox reaction, Rapid natural product modification, *Gem*-dimethyl tylophorine, Potent anti-proliferative activity, Druggability improvement

Natural products are an important source for drug discovery [1, 2]; however, many natural products are not suitable for use as drugs due to issues, such as poor solubility, stability, or toxicity. In addition, the complex molecular structures of these natural products make it difficult to modify them in a straightforward manner. As a result, the utilization and advancement of drugs


originating from natural products frequently encounter serious limitations [3-5]. Among the limitations, indolizidine scaffolds represent a group of pentacyclic natural products [6-9]. These characteristic skeletons have been reported to exhibit a wide range of biological activities, including anti-inflammatory, anti-cancer, anti-asthmatic, and immunosuppressive effects, as well

as antiviral activity against SARS-CoV-2. Tylophorine serves as a representative example of these diverse scaffolds [10-12].

This class of alkaloids has long-standing drawbacks, including severe central nervous system (CNS) side effects, low water solubility, and low metabolic stability, which severely limit its applications. Tylocrebrine, a similar natural product to tylophorine, was shown to be unsuitable in anti-cancer clinical trials in 1966 due to CNS toxicity [13]. To address these challenges, various strategies have been used to modify tylophorine. Specifically, the introduction of hydrophilic substituents [14], incorporation of quaternary ammonium salts [15], or preparation of uncyclized E-ring tylophorine [16] have been explored to enhance stability or aqueous solubility. Although these methods have made significant progress, reduced anti-proliferation activity has often occurred.

The *gem*-dimethyl group is an important and unique medicinal chemistry structural motif. Incorporation of the *gem*-dimethyl group into drug molecules provides benefits, such as stability, solubility, pharmacokinetics, and biological activity. This versatile functional group can be strategically introduced into a variety of compounds to optimize drug-like properties, which improves the likelihood of success in the drug discovery process [17-20]. One major advantage of incorporating *gem*-dimethyl groups into drug candidates is the ability to improve pharmacokinetic properties. Additionally, *gem*-dimethyl groups protect vulnerable sites from metabolic degradation, which prolongs compound half-life and increases overall stability [21]. *Gem*-dimethyl groups also have a crucial role in modulating the potency of a drug candidate [22]. Moreover, *gem*-dimethyl groups help optimize the conformation of a molecule, which can positively impact binding affinity and overall potency [23]. For the above reasons, the *gem*-dimethyl group has been utilized in the development of different therapeutic agents, including kinase inhibitors [24], transcription factor inhibitors [22], and β -lactamase inhibitors [25], to improve the drug-like properties and increase the likelihood of successful clinical development (Scheme 1).

A structure-activity relationship study of tylophorine demonstrated that the rigid phenanthrene structure is a prerequisite for high anti-cancer activity [13, 26, 27]. We reasoned, however, that this moiety can lead to strong intermolecular π - π stacking interactions, which results in poor aqueous solubility [28]. To address this issue, we strategically designed *gem*-dimethyl-tylophorine analogues, which are molecules with two methyl groups at the benzylic position of tylophorine. The steric hindrance effect of the methyl groups alters the molecular planarity, thereby potentially disrupting the intermolecular π - π interactions and improving aqueous solubility. Additionally, the increased hydrophilicity of the analogues may hinder the ability to cross the blood-brain barrier (BBB), potentially mitigating CNS side effects. Furthermore, the occupied benzylic position






Scheme 1 | Application of *gem*-dimethyl groups.

also enhances metabolic stability, thereby improving bioavailability (Scheme 2a). To test this hypothesis, we performed molecular simulations. As illustrated in Scheme 2b, the spatial conformation of the tylophorine backbone has a planar structure. The presence of the *gem*-dimethyl group introduces structural deviations from planarity. We hypothesized that this observation provide insight into the disruptive effects of the *gem*-dimethyl group, ultimately enhancing the drug-binding properties of tylophorine.

In the current study we present the design, synthesis, and evaluation of tylophorine *gem*-dimethyl analogues. We identified several lead compounds derived from tylophorine that exhibited excellent anti-cancer activities and significantly improved drug-like properties compared to tylophorine.

In our previous work we developed a novel photoredox-catalyzed cascade carboamination reaction that was successfully used in the synthesis of tylophorine and its *gem*-dimethyl analogues [29]. The diverse biological activities exhibited by tylophorine served as a source of inspiration for the discovery of rapid synthetic routes and novel bioactive molecules. Thus, we prepared compounds **1a-3a** and **1b-3b** (Figure 1) using our new synthetic method and performed preliminary biological activity tests to validate the accuracy of our approach. The MTS or CCK-8 assay was used to assess growth-inhibitory activity of these analogues against various cancer cell lines using doxorubicin and tylophorine as reference compounds (Table 1). Several *gem*-dimethyl-tylophorine analogues demonstrated potent anti-proliferative activity against a wide range of human refractory cancer cells. Notably, compound **1b** exhibited higher potency than tylophorine against the tested cancer cell lines, which was also observed when compared to doxorubicin in most cases. Compound **2b** displayed outstanding anti-proliferative activity, with IC_{50} values in the low nanomolar range and potency 2-10 times greater than tylophorine or doxorubicin in some cell lines (e.g., A549, H460, and Ramos). Moreover, compound **2b** exhibited significant anti-proliferation effects

Short Communication

a *Gem*-dimethyl effectb Simulations of the molecular spatial structure for the tylophorine backbone and its *gem*-dimethyl analogueScheme 2 | *Gem*-dimethyl incorporation strategy for the modification of tylophorine.Figure 1 | Synthetic route for *gem*-dimethyl tylophorine analogues.

on A549 (a human lung adenocarcinoma cell line) and MDA-MB-231 cells (a human breast cancer cell line) with IC_{50} values < 20 nM. While **compounds 1a**, **3a**, and **3b** did not exhibit anti-proliferative activity against the tested cancer cell lines, **compounds 1a**, **3a**, and **3b** provided valuable insight into the structure-activity relationship of tylophorine, which contributed to our understanding

of target protein recognition. The promising anti-cancer activity of **compounds 1b** and **2b** showed that *gem*-dimethyl-tylophorine analogues, enabled by this novel approach, could serve as potential hit compounds for further lead optimization.

Based on these findings, we initiated the design and synthesis of a new analogue, **compound 4b**, in which

the C-6 methoxy group was replaced with a hydroxyl group (**Figure 2a**). **Compound 4a** was obtained with a total yield of 33% through a catalytic carboamination

Table 1 | Anti-proliferative activities of *gem*-dimethyl-tylophorine analogues.

| Cell line | IC ₅₀ (nM) ^a | | | | |
|-------------------------|------------------------------------|-------------|-----------|-----------|------------------|
| | Doxorubicin | Tylophorine | 1b | 2b | 1a-3a, 3b |
| A549 ^b | 51.3 | 116.2 | 27.7 | 10.4 | >500 |
| K562 ^c | 71.3 | 95.0 | 57.7 | 30.2 | >500 |
| Ramos ^d | 111.0 | 86.6 | 75.8 | 30.6 | >500 |
| HBL-1 ^e | 49.2 | 81.9 | 50.9 | 29.0 | >500 |
| RKO ^f | 91.4 | 42.8 | 56.1 | 33.8 | >500 |
| MDA-MB-231 ^g | 85.0 | 41.5 | 35.8 | 19.7 | >500 |
| H460 ^h | 145.5 | 160.4 | 51.1 | 34.7 | >500 |
| HeLa ⁱ | 28.7 | 45.6 | 25.7 | 29.5 | >500 |

^aAll values are the mean of three experiments; ^bHuman lung adenocarcinoma cell line; ^cHuman chronic myeloid leukemia cell line; ^dHuman Burkitt's lymphoma cell line; ^eHuman diffuse large B-cell lymphoma cell line (BTK C481S mutant); ^fHuman colon cancer cell line; ^gHuman breast cancer cell line; ^hHuman lung cancer cell line; ⁱHuman cervical cancer cell line.

reaction, followed by deprotection of the Bn group and reduction to form **compound 4b**. The growth-inhibitory activities of **compound 4b** were subsequently assessed against K562 (a human chronic myeloid leukemia cell line) and MDA-MB-231 cells (a human breast cancer cell line), with **compound 2b** used as the control. **Compound 4b** had outstanding anti-proliferative activity with IC₅₀ values < 10 nM. Moreover, a notable 4-6-fold increase in potency was observed compared to **compound 2b** against both K562 and MDA-MB-231 cells. Even in HBL-1 cells, which exhibit resistance to ibrutinib (a human diffuse large B-cell lymphoma cell line [BTK C481S mutant]; ibrutinib GI₅₀ = 706.0 nM) [30], **compound 4b** demonstrated strong inhibition of cell growth, with an IC₅₀ value of approximately 7.8 nM. Considering the lack of effective drugs for treating ibrutinib-resistant non-Hodgkin's lymphoma, the potent activity of **compound 4b** suggests its potential for further development as a therapeutic option for this unmet medical need in the future (**Figure 2b-d**).

Subsequently, we performed tests on **compound 4b** using primary tumor cells derived from clinical patients [31] and compared the effects to paclitaxel and epirubicin. Remarkably, **compound 4b** exhibited excellent inhibition of tumor cell proliferation. Even in primary tumor cells resistant to paclitaxel or epirubicin, **compound 4b** displayed significant anti-tumor activity (**Figure 3**).




Figure 2 | Design, synthesis, and biological tests of **4b**.

^aAll values are the mean of at least three experiments. ^bHuman chronic myeloid leukemia cell line; ^cHuman breast cancer cell line; ^dHuman diffuse large B-cell lymphoma cell line (BTK C481S mutant).

Short Communication




Figure 3 | Biological tests of compound 4b in various human primary colon tumor cell lines.

All values are the mean of at least three experiments; statistical significance denoted as * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$, **** $P < 0.0001$; ns, not significant.

We then successfully separated the enantiomers of **compound 4b** and evaluated the anti-proliferative activities. The (-)-enantiomer of **compound 4b** demonstrated higher potency against the tested cancer cell lines compared to **compound 4b**, whereas the (+)-enantiomer of **compound 4b** exhibited only moderate anti-proliferative activity (Table 2).

Furthermore, we performed a general toxicity test on normal human bronchial epithelial cells (Beas-2b cell line). Compared to doxorubicin ($IC_{50} = 35.3$ nM), tylophorine and **compounds 1b, 2b, 4b, (-)-4b, and (+)-4b** exhibited significantly lower anti-proliferative activity

Table 2 | Biological tests of **compound 4b enantiomers.**

| Compound | IC_{50} (nM) ^a | |
|----------------|-----------------------------|-------------------------|
| | K562 ^b | MDA-MB-231 ^c |
| 4b | 12.5 | 9.5 |
| (-)- 4b | 4.3 | 2.7 |
| (+)- 4b | 341.8 | 253.3 |

^aAll values are the mean of at least three experiments;

^bHuman chronic myeloid leukemia cell line; ^cHuman breast cancer cell line.

against the tested normal cell line, as indicated by the higher IC_{50} values (Table 3) [32]. These findings suggest a potentially improved therapeutic window for the newly derived *gem*-dimethyl-tylophorine analogues. Although phenanthroindolizidine alkaloids, such as tylophorine,

Table 3 | Toxicity and solubility tests of the *gem*-dimethyl-tylophorine analogues.

| Compound | Toxicity, IC_{50} (nM) ^a | Solubility | |
|----------------|---------------------------------------|----------------------|-------------------------------|
| | | Beas-2b ^b | Aqueous solution ^c |
| Doxorubicin | 35.3 | | |
| Tylophorine | 627.9 | < 1 mM | < 10 ug/mL ^d |
| 1b | 828.8 | | |
| 2b | 614.0 | | |
| 4b | 388.7 | > 500 mM | > 200 ug/mL |
| (-)- 4b | 314.5 | | |

^aAll values are the mean of at least three experiments.

^bHuman bronchial epithelial cell line; ^cAqueous solubility was tested in phosphate buffered saline, (PBS [pH = 7.2–7.4]);

^dTested solubility data agreed with the literature reported value [15].




Figure 4 | Comparison of stability between tylophorine and compound 4b monitored by ^1H NMR.

Short Communication

have diverse biological activities, the poor solubility has severely limited clinical use. To address this issue, we performed solubility tests comparing tylophorine to our newly synthesized derivative, **compound 4b**. As depicted in **Table 3**, the solubility of tylophorine was < 1 mM, whereas **compound 4b** exhibited a solubility value > 500 mM. Notably, the aqueous solubility of **4b** in phosphate-buffered saline (PBS) was measured to be > 200 µg/mL, which was significantly higher than tylophorine (<10 µg/mL). The improved solubility of **compound 4b** may reduce the tendency to cross the BBB, thereby potentially minimizing CNS side effects (**Table 3**).

Furthermore, while tylophorine is easily decomposed in organic solvents [15], our *gem*-dimethyl-tylophorine analogue, **compound 4b**, demonstrated no detectable degradation as observed by ¹H NMR analysis after at least 1 week, indicating increased stability (**Figure 4**). This was an encouraging finding, suggesting that our approach offers a promising strategy for enhancing the pharmacologic and drug-like properties of phenanthroindolizidine alkaloids.

In summary, the *gem*-dimethyl group represents a valuable medicinal chemistry structural motif, offering potential benefits in terms of pharmacokinetic properties, potency, selectivity, and metabolic stability. We synthesized a series of tylophorine derivatives using a novel photoredox promoted reaction. Among the tylophorine derivatives, **compound 4b** exhibited remarkable anti-proliferative activities with IC₅₀ values < 10 nM against 8 human cancer cell lines, including K562, MDA-MB-231, and C481S HBL-1, as well as primary tumor cell lines from patients. **Compound 4b** demonstrated a remarkably strong inhibitory effect (7.8 nM) against ibrutinib-resistant C481S HBL-1 tumor cells, especially for C481S ibrutinib-resistant non-Hodgkin's lymphoma, which is due to a cysteine-to-serine mutation at position 481. Because there is currently no available therapeutic drug for ibrutinib-resistant non-Hodgkin's lymphoma treatment, **compound 4b** should undergo further development for addressing this challenging medical problem in the future. Furthermore, **compound 4b** exhibited significant improvements in solubility and stability compared to tylophorine. Hence, there is hope that **compound 4b** can effectively address the drawbacks associated with tylophorine, thereby expanding its utilization and clinical application. Taken together, we believe our study may pave the way for developing new therapeutic agents for potential drug-resistant cancer treatment. With the strategic incorporation of *gem*-dimethyl groups, researchers can optimize drug candidates for improved efficacy and safety, ultimately contributing to the development of new and innovative therapeutics.

ACKNOWLEDGEMENTS

This work was supported by the National Natural Science Foundation of China (#82125034) and National Key R&D Program of China (#2020YFE0202200, #2021YFA1300200, and #2021YFA1302100).

CONFLICTS OF INTEREST

The authors hold patent applications for some compounds described in this manuscript (CN110283170B). There are no further competing interests to declare.

REFERENCES

- [1] Bradaric M: Review of Pharmacological Advances in Natural Product Drug Discovery. *Journal of Natural Products* 2021, 84:1860.
- [2] Newman DJ: Natural Products and Drug Discovery. *National Science Review* 2022, 9:nwac206.
- [3] Allred TK, Manoni F, Harran PG: Exploring the Boundaries of "Practical": De Novo Syntheses of Complex Natural Product-Based Drug Candidates. *Chemical Reviews* 2017, 117:11994–12051.
- [4] Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT: Natural Products in Drug Discovery: Advances and Opportunities. *Nature Reviews Drug Discovery* 2021, 20:200–216.
- [5] Zhou X, Li W, Zhou R, Wu X, Huang Y, Hou W, et al.: Bioinspired Scalable Total Synthesis of Opioids. *CCS Chemistry* 2021, 3:1376–1383.
- [6] Gellert E: The Indolizidine Alkaloids. *Journal of Natural Products* 1982, 45:50–73.
- [7] Sharma V, Kamal R, Kumar D, Kumar V: Indolizidine Alkaloids: Prospective Lead Molecules in Medicinal Chemistry. *Current Traditional Medicine* 2021, 7:45–56.
- [8] Xuan J, Haelsig KT, Sheremet M, Machicao PA, Maimone TJ: Evolution of a Synthetic Strategy for Complex Polypyrrole Alkaloids: Total Syntheses of Curvulamine and Curindolizine. *Journal of the American Chemical Society* 2021, 143:2970–2983.
- [9] Zhu M, Huang XL, Xu H, Zhang X, Zheng C, You SL: Visible-Light-Mediated Synthesis of Cyclobutene-Fused Indolizidines and Related Structural Analogs. *CCS Chemistry* 2021, 3:652–664.
- [10] Cyriac A, Thomas T, Thomas TD: Tylophorine: Sources, Properties, Applications and Biotechnological Production. In *Plant-Derived Bioactives*. Edited by Swamy M. Singapore: Springer; 2020;167–176.
- [11] Wang Z, Ye F, Feng Y, Xiao W, Song H, Zhao L, et al.: Discovery and Nanosized Preparations of (S,R)-Tylophorine Malate as Novel anti-SARS-CoV-2 Agents. *ACS Medicinal Chemistry Letters* 2021, 12:1840–1846.
- [12] Omran Z, Abdullah O, Sindi IA, Altyar A, Batubara AS. U.S. Quaternary Ammonium Salts of Phenanthroindolizidine and Phenanthroquinolizidine Alkaloids as Hypoxia-Targeted Anticancer Agents. U.S. Patent No. US11548891 B1, 2023.
- [13] Wei LY, Shi Q, Bastow KF, Brossi A, Morris-Natschke SL, Nakagawa-Goto K, et al.: Antitumor Agents 253. Design, Synthesis, and Antitumor Evaluation of Novel 9-Substituted Phenanthrene-Based Tylophorine Derivatives as Potential Anticancer Agents. *Journal of Medicinal Chemistry* 2007, 50:3674–3680.
- [14] Kwon Y, Song J, Lee B, In J, Song H, Chung HJ, et al.: Design, Synthesis, and Evaluation of a Water-Soluble Antofine Analogue with High Antiproliferative and Antitumor Activity. *Bioorganic and Medicinal Chemistry* 2013, 21:1006–1017.
- [15] Han G, Chen L, Wang Q, Wu M, Liu Y, Wang Q: Design, Synthesis, and Antitobacco Mosaic Virus Activity of Water-Soluble Chiral Quaternary Ammonium Salts of

- Phenanthroindolizidines Alkaloids. *Journal of Agricultural and Food Chemistry* 2018, 66:780–788.
- [16] Yang X, Shi Q, Liu Y-N, Zhao G, Bastow KF, Lin J-C, et al. Antitumor Agents 268. Design, Synthesis, and Mechanistic Studies of New 9-Substituted Phenanthrene-Based Tylophorine Analogues as Potent Cytotoxic Agents. *Journal of Medicinal Chemistry* 2009, 52:5262–5268.
- [17] Talele TT: Natural-Products-Inspired Use of the Gem-Dimethyl Group in Medicinal Chemistry. *Journal of Medicinal Chemistry* 2018, 61:2166–2210.
- [18] Rathnayake AD, Kim Y, Dampalla CS, Nguyen HN, Jesri ARM, Kashipathy MM, et al.: Structure-Guided Optimization of Dipeptidyl Inhibitors of Norovirus 3CL Protease. *Journal of Medicinal Chemistry* 2020, 63:11945–11963.
- [19] Sun H, Cardinal KA, Wienkers L, Chin A, Kumar V, Neace C, et al.: Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl. *Cancer Chemotherapy and Pharmacology* 2022, 89:737–750.
- [20] Dampalla CS, Miller MJ, Kim Y, Zabiegala A, Nguyen HN, Madden TK, et al.: Structure-Guided Design of Direct-Acting Antivirals that Exploit the Gem-Dimethyl Effect and Potently Inhibit 3CL Proteases of Severe acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). *European Journal of Medicinal Chemistry* 2023, 254:115376.
- [21] Shi J, van de Water R, Hong K, Lamer RB, Weichert KW, Sandoval CM, et al.: EC144 is a potent inhibitor of the heat shock protein 90. *Journal of Medicinal Chemistry* 2012, 55:7786–7795.
- [22] Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al.: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. *Science* 2009, 324:787–790.
- [23] Han S, Caspers N, Zaniewski RP, Lacey BM, Tomaras AP, Feng X, et al.: Distinctive Attributes of β -Lactam Target Proteins in *Acinetobacter baumannii* Relevant to Development of New Antibiotics. *Journal of the American Chemical Society* 2011, 133:20536–20545.
- [24] Ndubaku CO, Heffron TP, Staben ST, Baumgardner M, Blaquiére N, Bradley E, et al.: Discovery of 2-[3-[2-(1-Isopropyl-3-Methyl-1H-1,2,4-Triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-Pyrazol-1-yl]-2-Methylpropanamide (GDC-0032): A β -sparing phosphoinositide 3-kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity. *Journal of Medicinal Chemistry* 2013, 56:4597–4610.
- [25] Hinchliffe P, Gonzalez MM, Mojica MF, González JM, Castillo V, Saiz C, et al.: Cross-Class Metallo-B-Lactamase Inhibition by Bisthiazolidines Reveals Multiple Binding Modes. *Proceedings of the National Academy of Sciences of the United States of America* 2016, 113:3745–3754.
- [26] Lee YZ, Yang CW, Hsu HY, Qiu YQ, Yeh TK, Chang HY, et al.: Synthesis and Biological Evaluation of Tylophorine-Derived Dibenzoquinolines as Orally Active Agents: Exploration of the Role of Tylophorine E Ring on Biological Activity. *Journal of Medicinal Chemistry* 2012, 55:10363–10377.
- [27] Mang Z, Zhang S, Bai J, Li M, Li H. Design, Synthesis and in Vitro Evaluation of Tylophorine Derivatives as Possible Antitumor Agents. *Chemistry & Biodiversity* 2020, 17: e2000066.
- [28] Deogratias G, Shadrack DM, Munissi JJE, Kinunda GA, Jacob FR, Mtei RP, et al. Hydrophobic π - π Stacking Interactions and Hydrogen Bonds Drive Self-Aggregation of Luteolin in Water. *Journal of Molecular Graphics and Modelling* 2022, 116:108243.
- [29] Zhang C, Wang Y, Song Y, Gao H, Sun Y, Sun X, et al.: Synthesis of Quaternary Carbon-Centered Benzoindolizidinones via Novel Photoredox-Catalyzed Alkene Aminoarylation: Facile Access to Tylophorine and Analogues. *CCS Chemistry* 2019, 1:352–364.
- [30] Sun Y, Zhao X, Ding N, Gao H, Wu Y, Yang Y, et al.: PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. *Cell Research* 2018, 28:779–781.
- [31] Yin S, Xi R, Wu A, Wang S, Li Y, Wang C, et al.: Patient-Derived Tumor-Like Cell Clusters for Drug Testing in Cancer Therapy. *Science Translational Medicine* 2020, 12:eaaz1723.
- [32] Lin JC, Yang SC, Hong TM, Yu SL, Shi Q, Wei L, et al.: Phenanthrene-Based Tylophorine-1 (PBT-1) Inhibits Lung Cancer Cell Growth through the Akt and NF-KB Pathways. *Journal of Medicinal Chemistry* 2009, 52:1903–1911.